They ought to be able to get new use patents on several other diseases by then … volume pipeline built up with Vascepa that allows them to drive pricing to such an extent that it inhibits the ability of others--even generics--to compete
Yes … but they have an agreement in place with TEVA - they could launch gV by 2029 - they could match / compete with Amarin's price … which will be significantly lower after launch of gV
No need to explain it to the genius...Also trademarking Vascepa is not going away in 1929...Amarin could develop its own DS EPA...But please don't point this out to the know it all...
Tatsu....Don't call me a curmudgeon which is prejudicial..I know you would be on the mat if someone made a prejudicial remark to you..
Keep in mind I've posted a lot more than you have and have a better batting average regardless of my age...
EPA fun time is far from over by 2029 for AMRN. They ought to be able to get new use patents on several other diseases by then, in addition to having a volume pipeline built up with Vascepa that allows them to drive pricing to such an extent that it inhibits the ability of others--even generics--to compete.
Catchin' up with about 500 posts tonight. Spent Saturday hustling a Road Glide full dresser up over Donner pass and into Reno, the signs all said something about a Donner Party at the summit, but we had stuff to do/places to go. Next time. The hard part was playing sport bike lanes splitting from Sacramento to SF Sunday w/ everybody watching the Blue Angels on the bridge.. I ain't too old yet. But if the posts stop, you'll know.... I'll post about the SF Reduce It Party before I shut it down tonight.
Newbies, Look at JL's posts about healing and Dry Eye. I got a handful about arthritis and a friend who did too much jumping out of airplanes with a full backpack and some ancillary stuff said positive stuff this weekend, details to come. I've posted stuff about my wife's Parkinsons and arthritis, see North400K's blood work. Spend a day reading and forego all of us reliving 7 years of learning and progress. There's a lot of fire power here over a lot of years, take advantage of it.
EPA is not a parenteral, GMP is tedious/easy at food grade level.. Suppliers are not the immediate issue, feedstock is. At 25% RRR/already on the market, the FDA will discount the isomorphism issue between the study and real life and bless it.